Vimarsana
Biggest News Aggregation in the World

Page 19 - Acceleron Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Today - Breaking & Trending Today

STELLAR, 'Impressive' Results With Novel Drug Sotatercept in PAH - Vimarsana News

STELLAR, 'Impressive' Results With Novel Drug Sotatercept in PAH

The randomized trial of this first-in-class injectable drew sustained applause at ACC 2023 when results were presented.

Source: tctmd.com
Merck's drug boosts exercise capacity in pulmonary hypertension patients - Vimarsana News

Merck's drug boosts exercise capacity in pulmonary hypertension patients

(Reuters) -Merck & Co Inc said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease th...

Source: whbl.com
Bristol Myers Squibb Receives European Commission Approval of Reblozyl (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia - Vimarsana News

Bristol Myers Squibb Receives European Commission Approval of Reblozyl (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission

Eisenmenger Complex Management Market to reach US$ 12.9 billion in 2033, Endothelin Receptors to acc - Vimarsana News

Eisenmenger Complex Management Market to reach US$ 12.9 billion in 2033, Endothelin Receptors to acc

The global Eisenmenger complex management market is expected to surpass an impressive valuation of US$ 7.7 billion in 2023 and is projected to reach US$ 12.9 billion by 2033, growing at a CAGR of 5.3%. Generally, the treatment includes relieving the symptoms and associated co-morbidities. Medications such as calcium...

Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progr - Vimarsana News

Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progr

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of clinical data from its broad and advancing cardiovascular pipeline and portfolio at the upcoming American College of Cardiology’s 72nd Annual Scientific Session toget...